2012/12/27 |
2012年12月27日(水)14:30-15:30
三重大学環境・情報科学館3階において、記者会見を行いました。
【新しい知見について研究成果発表】
食行動を制御する遺伝子と医薬品のハイスピード探索法開発に成功
肥満や神経性食欲不振症は、代表的な現代病で食行動異常が基礎にあります。そこで、これらの新しい治療法を実現するために、食行動を制御する遺伝子や医薬品を発見するハイスピード探索システムを開発しました。
このシステムでは、世界で使用されているすべての食欲抑制薬の作用を解析できるだけではなく、全く新しい食行動制御薬や食行動調節遺伝子を、ハイスピードで探索することが可能ですので、すべての遺伝子(ゲノム)や化合物を解析することができます。
また、詳細は、学術誌PLOS ONEに掲載されます。
A High-Throughput Fluorescence-Based Assay System for Appetite-Regulating Gene and Drug Screening
Yasuhito Shimada,Minoru Hirano, Yuhei Nishimura, Toshio Tanaka
Abstract
The increasing number of people suffering from metabolic syndrome and obesity is becoming a serious problem not only in developed countries, but also in developing countries. However, there are few agents currently approved for the treatment of obesity. Those that are available are mainly appetite suppressants and gastrointestinal fat blockers. We have developed a simple and rapid method for the measurement of the feeding volume of Danio rerio (zebrafish). This assay can be used to screen appetite suppressants and enhancers. In this study, zebrafish were fed viable paramecia that were fluorescently-labeled, and feeding volume was measured using a 96-well microplate reader. Gene expression analysis of brain-derived neurotrophic factor (bdnf), knockdown of appetite-regulating genes (neuropeptide Y, preproinsulin, melanocortin 4 receptor, agouti related protein, and cannabinoid receptor 1), and the administration of clinical appetite suppressants (fluoxetine, sibutramine, mazindol, phentermine, and rimonabant) revealed the similarity among mechanisms regulating appetite in zebrafish and mammals. In combination with behavioral analysis, we were able to evaluate adverse effects on locomotor activities from gene knockdown and chemical treatments. In conclusion, we have developed an assay that uses zebrafish, which can be applied to high-throughput screening and target gene discovery for appetite suppressants and enhancers.